Results 301 to 310 of about 1,317,331 (364)

Managing Diabetes One Step at a Time in Low‐ and Middle‐Income Countries: The Promise of Wearable Devices

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The global burden of diabetes mellitus disproportionately affects low‐ and middle‐income countries (LMICs), where limited healthcare infrastructure hampers timely and effective disease management. Wearable technologies, such as continuous glucose monitors (CGMs), insulin pumps, and fitness trackers, offer a transformative opportunity to bridge
Safayet Jamil, Masoud Mohammadnezhad, Abdulrakib Abdulrahim, Faisal Muhammad, Hafiz T. A. Khan   +4 more
wiley   +1 more source

Willingness to accept capitation payment system under the Ghana National Health Insurance Policy: do income levels matter? [PDF]

Health Econ Rev, 2017
Sackey FG, Amponsah PN.
europepmc   +1 more source

LGBTQ+ Affirmative Care Training in Counselor Education: A Community‐Based Inquiry

Counselor Education and Supervision, EarlyView.
ABSTRACT Counselor educators, counselors‐in‐training, and LGBTQ+ community members engaged in a community‐based qualitative inquiry exploring LGBTQ+ affirmative care education. Findings revealed counselor educators’ components and delivery of content, developmental implications for applying LGBTQ+ affirmative care, and gaps between education and LGBTQ+
Nancy E. Thacker Darrow, Kamden K. Strunk, Thea L. Racelis   +2 more
wiley   +1 more source

Smoking and insurance policies.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1979
openaire   +2 more sources

ESG Messaging on Social Media and Cost of Capital: A Canadian Perspective

Canadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, EarlyView.
ABSTRACT We examine whether environmental, social and governance (ESG) communications on social media decrease firms' cost of equity. Our results show that ESG messaging on social media does not appear to influence investors, which leads us to examine why.
Dhruv Baswal, Sean Cleary
wiley   +1 more source

Factors Influencing the Duration From the Initiation of Surgical Evaluation to Final Intervention in Pediatric Epilepsy Surgery

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Rationale Longer duration of epilepsy before surgery is a predictor of poor outcome. While referral delays of surgical candidates are well documented, factors causing delay during the presurgical evaluation remain unclear and may vary depending on institutional characteristics.
Ruba Al‐Ramadhani, Ann Hyslop, Avery R. Caraway, Edward J. Novotny, Adam P. Ostendorf, Krista L. Eschbach, Allyson L. Alexander, Lily C. Wong‐Kisiel, Dewi F. Depositario‐Cabacar, Chima O. Oluigbo, Cemal Karakas, Samir R. Karia, Priyamvada Tatachar, Jeffrey Bolton, Pilar D. Pichon, Daniel W. Shrey, Erin Fedak Romanowski, Nancy A. McNamara, Ernesto Gonzalez‐Giraldo, Kurtis Auguste, Danilo Bernardo, Rani K. Singh, Pradeep K. Javarayee, Jenny J. Lin, Jason C. Coryell, Shilpa B. Reddy, Abhinaya Ganesh, Michael A. Ciliberto, Debopam Samanta, Kristen H. Arredondo, Ahmad Marashly, Zachary M. Grinspan, Dallas Armstrong, Taylor J. Abel, Janelle Wagner, Derryl J. Miller, Fernando N. Galan, Michael Scott Perry   +37 more
wiley   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

Clinical Pharmacology &Therapeutics, EarlyView.
The potential of real‐world data (RWD), particularly from patient registries, has been increasingly recognized over the last decade by academia, regulators, and health technology assessment (HTA) bodies for its role in assessing a product's effectiveness and supporting regulatory submissions.
Sonia Zebachi, Julien Tanniou, Elisabeth Bakker, Sieta T. de Vries, Rossella Di Bidino, Entela Xoxi, Anna Glaser, Gianluigi Savarese, Jan Hillert, Peter G. M. Mol, Kelly Plueschke, Billy Amzal, Ghinwa Y. Hayek, Jeverson Moreira   +13 more
wiley   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source